Recent progress in cannabinoid research (Q36477479)

14 August 2017

1 reference

title

Recent progress in cannabinoid research (English)

1 reference

14 August 2017

0 references

Julia Adam

1

1 reference

14 August 2017

Phillip M Cowley

2

1 reference

14 August 2017

Takao Kiyoi

3

1 reference

14 August 2017

Angus J Morrison

4

1 reference

14 August 2017

Christopher J W Mort

5

1 reference

14 August 2017

1 January 2006

1 reference

Progress in medicinal chemistry

14 August 2017

1 reference

14 August 2017

44

1 reference

14 August 2017

207-329

1 reference

Towards cannabinoid drugs--revisited.

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cannabinergic ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Evidence for novel cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The endocannabinoid system: a general view and latest additions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The endocannabinoid system and its therapeutic exploitation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The molecular logic of endocannabinoid signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Evidence against the presence of an anandamide transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The fatty acid amide hydrolase (FAAH)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Endocannabinoid Transporter Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

1 reference

7 January 2021

Structural determinants for recognition and translocation by the anandamide transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Novel selective and metabolically stable inhibitors of anandamide cellular uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Anandamide hydrolysis by human cells in culture and brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The enzymatic inactivation of the fatty acid amide class of signaling lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Effects of anandamide on cannabinoid receptors in rat brain membranes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Influence of phenylmethylsulfonyl fluoride on anandamide brain levels and pharmacological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Heterocyclic sulfoxide and sulfone inhibitors of fatty acid amide hydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Modulation of anxiety through blockade of anandamide hydrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

An endogenous sleep-inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The molecular basis of cannabinoid activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structure-activity relationships of cannabinoids: a joint CoMFA and pseudoreceptor modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Tetrahydrocannabinol homologs with double branched alkyl groups in the 3-position

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and pharmacology of the isomeric methylheptyl-delta8-tetrahydrocannabinols.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structure-activity relationships for 1',1'-dimethylalkyl-Delta8-tetrahydrocannabinols

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Novel conformationally restricted tetracyclic analogs of delta8-tetrahydrocannabinol

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Molecular probes for the cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

A novel class of potent tetrahydrocannabinols (THCS): 2'-yne-delta 8- and delta 9-THCS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

An investigation into the structural determinants of cannabinoid receptor ligand efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and testing of novel phenyl substituted side-Chain analogues of classical cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pharmacological evaluation of halogenated Δ8-THC analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Comparison in mice of pharmacological effects of Δ8-tetrahydrocannabinol and its metabolites oxidized at 11-position

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and pharmacological activity of some 9-substituted .DELTA.8-tetrahydrocannabinol (THC) analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structural requirements for cannabinoid-induced antinociceptive activity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Hu 210: a potent tool for investigations of the cannabinoid system.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Ajulemic acid (CT3): a potent analog of the acid metabolites of THC.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Ajulemic acid: A novel cannabinoid produces analgesia without a "high"

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and antitumor activity of quinonoid derivatives of cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

A cannabinoid derived prototypical analgesic

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Conformational analysis of the prototype nonclassical cannabinoid CP-47,497, using 2D NMR and computer molecular modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Classical/non-classical cannabinoid hybrids; stereochemical requirements for the southern hydroxyalkyl chain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Natural and synthetic endocannabinoids and their structure-activity relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Discovery and characterization of endogenous cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pharmacological and behavioral evaluation of alkylated anandamide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Potent Anandamide Analogs: The Effect of Changing the Length and Branching of the End Pentyl Chain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Preferred conformations of endogenous cannabinoid ligand anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Unique Analogues of Anandamide: Arachidonyl Ethers and Carbamates and Norarachidonyl Carbamates and Ureas

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

A second endogenous cannabinoid that modulates long-term potentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Brain monoglyceride lipase participating in endocannabinoid inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and biological activities of novel structural analogues of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB(1) receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

C-Attached aminoalkylindoles: potent cannabinoid mimetics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and pharmacology of a hybrid cannabinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Importance of the C-1 Substituent in Classical Cannabinoids to CB2Receptor Selectivity: Synthesis and Characterization of a Series ofO,2-Propano-Δ8-tetrahydrocannabinol Analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

C-3 Amido-indole cannabinoid receptor modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Rational Design and Synthesis of an Orally Active Indolopyridone as a Novel Conformationally Constrained Cannabinoid Ligand Possessing Antiinflammatory Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

A pyridone analogue of traditional cannabinoids. A new class of selective ligands for the CB(2) receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

IACM 2nd Conference on Cannabinoids in Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Analgesic Effect of Delta‐9‐Tetrahydrocannabinol

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Are oral cannabinoids safe and effective in refractory neuropathic pain?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Pain relief with oral cannabinoids in familial Mediterranean fever

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cannabinoid agonists attenuate capsaicin-induced responses in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

General Articles Cannabinoids: Mechanisms and Therapeutic Applications in the CNS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cannabinoids and glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The role of sensory nerve endings in nerve growth factor-induced airway hyperresponsiveness to histamine in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Development of a 3D model for the human cannabinoid CB1 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

An Aromatic Microdomain at the Cannabinoid CB1 Receptor Constitutes an Agonist/Inverse Agonist Binding Region

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

3-Alkyl-(5,5'-diphenyl)imidazolidineiones as new cannabinoid receptor ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Molecular lipophilicity potential, a tool in 3D QSAR: method and applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Endogenous cannabinoid system as a modulator of food intake

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Leptin-regulated endocannabinoids are involved in maintaining food intake

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cannabinoids and the regulation of ingestive behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944406-9

7 January 2021

10.1016/S0079-6468(05)44406-9

Identifiers

DOI

1 reference

release_qromdtwhfbad5i3n2j2naaabhm

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qromdtwhfbad5i3n2j2naaabhm

24 November 2022

mapped directly with Wikidata item

1 reference